Dorr R T, Dvorakova K, Brooks C, Lines R, Levine N, Schram K, Miketova P, Hruby V, Alberts D S
Department of Pharmacology and Arizona Cancer Center, Tucson 85724, USA.
Photochem Photobiol. 2000 Oct;72(4):526-32. doi: 10.1562/0031-8655(2000)072<0526:ieeati>2.0.co;2.
Seven normal volunteers (six males and one female) with tanning skin types III or IV (Fitzpatrick scale) were given 10 daily subcutaneous injections of a superpotent synthetic analog of alpha-melanocyte stimulating hormone (alpha-MSH) over two weeks. This agent, [Nle4-D-Phe7]alpha-MSH, also called Melanotan-I (MT-I), was administered at a dose of 0.16 mg/kg/day (Monday-Friday), over a two week period. Tanning was measured serially using computerized light reflectance. This regimen induced tanning at 3 of 8 anatomic sites including the face, neck and forearm by comparison of baseline to (1) the end of the daily dosing period, (day 14), and (2) one week later, (day 21). Shave biopsies of the forearm taken at baseline and day 21 were analyzed by high performance liquid chromatography for eumelanin content which was measured as the permanganate oxidation product, pyrrole-2,3,5-tricarboxylic acid or PTCA. Pheomelanin content was measured as the hydroiodic acid digestion product, aminohydroxyphenylalanine (AHP). Eumelanin was also measured in the forehead skin samples of three subjects. The HPLC results show that mean (+/- SD) baseline eumelanin (PTCA) levels in forehead skin (n = 3) averaged 1.38 (+/- 0.87) ng/mg of wet skin tissue weight. Higher mean baseline levels of PTCA were detected in forearm skin (2.06 +/- 0.28 ng/mg wet weight, n = 7). One week after MT-I treatments ended, there was a mean (SD) 49% (+/- 17.6%) increase in forehead skin PTCA levels compared to baseline (P = 0.019, n = 3, by paired sample T-test). The mean (SD) increase in forearm skin PTCA levels was 98% (+/- 25.4%) over the same period (P = 0.003). In contrast, forearm pheomelanin expression following MT-I treatment did not significantly change from baseline. Overall, the MT-I regimen increased the eumelanin: pheomelanin ratio in forearm skin from 51:1 at baseline to 86:1 following MT-I (P = 0.054 by paired sample T-test). These results show that the tanning induced by MT-I in the face and forearm is associated with a significant increase in the eumelanin content of the human skin.
七名皮肤类型为III或IV型(菲茨帕特里克量表)的正常志愿者(六名男性和一名女性)在两周内每天接受10次皮下注射一种超效合成α-黑素细胞刺激激素(α-MSH)类似物。这种药物,[Nle4-D-Phe7]α-MSH,也称为美拉诺坦-I(MT-I),以0.16mg/kg/天的剂量(周一至周五)给药,为期两周。使用计算机化光反射率连续测量晒黑情况。通过比较基线与(1)每日给药期结束时(第14天)以及(2)一周后(第21天),该方案在包括面部、颈部和前臂在内的8个解剖部位中的3个部位诱导了晒黑。在基线和第21天采集的前臂剃须活检组织通过高效液相色谱法分析真黑素含量,其以高锰酸盐氧化产物吡咯-2,3,5-三羧酸或PTCA来测量。褐黑素含量以氢碘酸消化产物氨基羟基苯丙氨酸(AHP)来测量。还对三名受试者的前额皮肤样本中的真黑素进行了测量。高效液相色谱结果显示,前额皮肤(n = 3)中真黑素(PTCA)的平均(±标准差)基线水平平均为1.38(±0.87)ng/mg湿皮肤组织重量。在前臂皮肤中检测到更高的PTCA平均基线水平(2.06±0.28 ng/mg湿重,n = 7)。MT-I治疗结束一周后,与基线相比,前额皮肤PTCA水平平均(标准差)增加了49%(±17.6%)(配对样本T检验,P = 0.019,n = 3)。同期前臂皮肤PTCA水平的平均(标准差)增加为98%(±25.4%)(P = 0.003)。相比之下,MT-I治疗后前臂褐黑素表达与基线相比没有显著变化。总体而言,MT-I方案使前臂皮肤中真黑素与褐黑素的比例从基线时的51:1增加到MT-I治疗后的86:1(配对样本T检验,P = 0.054)。这些结果表明,MT-I在面部和前臂诱导的晒黑与人体皮肤中真黑素含量的显著增加有关。